Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and ...
Patients with chronic spontaneous urticaria and positive CU Index results or a combination of low IgE and low blood histamine ...
Please provide your email address to receive an email when new articles are posted on . Omlyclo is approved to treat the same four conditions as omalizumab. There are now three doses/solutions of ...
BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S ...
In an observational cohort study of patients with chronic spontaneous urticaria, fast responders to omalizumab (≤ 1 month) had the longest drug survival (median, 3.9 years) and required lower ...
Patients who take omalizumab prior to starting oral immunotherapy (OIT) may skip much of the latter treatment’s onerous dose escalation process, according to a new study presented at the American ...
Researchers at the Institut Pasteur have developed a vaccine that spurred the production of autoantibodies to immunoglobulin E (IgE) antibodies, protecting vaccinated mice from anaphylaxis. In their ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Kashiv Biosciences has submitted its Biologics License Applications (BLA) for ADL-018 as a biosimilar to reference product XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA) The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results